Dr. Wu has served XBiotech as VP of Quality Control since July 2017. She oversees quality control function to support CMC and clinical operations, including in process, release, stability testing of API and drug product, Microbiology and Environmental Monitoring, analytical development and validation, Raw Material testing, Critical Reagents and Reference Standard, Comparability Studies and clinical pharmacokinetics, pharmacodynamic, and anti-drug antibody testing. Dr. Wu initially joined XBiotech team in 2011 as a Senior Scientist of Analytical Development. She has a B.S degree in Biochemistry and Molecular Biology from Peking University (China), and a Ph.D degree in Biochemistry from Texas A&M University. She went to University of Texas Southwestern Medical Center at Dallas for post-doctoral research. Her work in graduate school and post-doctoral research were published in ten peer-reviewed journal articles and were mainly focused on elucidating mechanisms of action for nuclear and non-nuclear pathways for estrogen and xenoestrogens in cancer and other clinical conditions, utilizing both in-vitro and in-vivo models.